Voronoi Inc
KOSDAQ:310210
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (43.9), the stock would be worth ₩-119 943.81 (139% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -112.2 | ₩307 000 |
0%
|
| Industry Average | 43.9 | ₩-119 943.81 |
-139%
|
| Country Average | 12.5 | ₩-34 298.97 |
-111%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
V
|
Voronoi Inc
KOSDAQ:310210
|
5.5T KRW | -112.2 | -116.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.4B USD | 19.9 | 86 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
191.5B USD | 14.2 | 24.5 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
170.8B USD | 15.3 | 19.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.1B USD | 22.1 | 28.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.3B USD | 14.9 | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.8B EUR | 43.9 | 39.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 13.7 | 32.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7.8 |
| Median | 12.5 |
| 70th Percentile | 23.2 |
| Max | 13 874.5 |
Other Multiples
Voronoi Inc
Glance View
Voronoi, Inc. engages in the manufacture of novel kinase inhibitors and target protein degrader drugs. The company is headquartered in Incheon, Incheon. The company went IPO on 2022-06-24. The firm is principally engaged in the technology transfer of new drug candidates prior to electroclinical clinical trials. The firm is principally engaged in the research and development of kinase inhibitor as well as others. In addition, the Company is also engaged in the building and supply of new drug development platforms based on artificial intelligence (AI) and research results.
